durvalumab

News

After looking like it could get left far behind by rivals in immunotherapy, AstraZeneca has made its first filing for PD-L1 drug durvalumab .

News

Scribe Therapeutics has become the latest biotech to announce plans to list on the Nasdaq as it advances its spin on CRISPR-based therapeutics.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.